Side Effects of Clopidogrel

Major Side Effects

Hemorrhage is reported in 4.8-8.1% of patients taking clopidogrel 1
Gastrointestinal bleeding risk is significantly increased, especially when combined with aspirin, with dual antiplatelet therapy increasing GI bleeding risk by up to 70%, according to the American College of Cardiology 2, 3
Thrombotic thrombocytopenic purpura (TTP) is a rare but serious complication that can occur within 14 days after starting clopidogrel, with the American Heart Association citing it as a potential risk 4
Unlike ticlopidine, clopidogrel does not commonly cause neutropenia, as noted by the American College of Cardiology 5

Concomitant use of anticoagulants like warfarin increases the risk of bleeding, according to the American College of Cardiology 3
Concomitant use of certain proton pump inhibitors, such as omeprazole and esomeprazole, reduces the effectiveness of clopidogrel, as reported by the American Heart Association 6

Clopidogrel should be discontinued 5-7 days before elective surgery with major bleeding risk, as recommended by the American College of Cardiology 7, 2
For high-risk endoscopic procedures, guidelines recommend withholding clopidogrel for at least 7 days, according to the American College of Cardiology 2
Avoid concomitant use with omeprazole or esomeprazole due to reduced effectiveness of clopidogrel, as advised by the American Heart Association 6

Unlike ticlopidine, routine blood count monitoring is not required for clopidogrel, as stated by the American Heart Association 4

Consider prophylactic proton pump inhibitor therapy in patients at high risk for GI bleeding, as recommended by the American College of Cardiology 2
For patients with a history of GI bleeding who require antiplatelet therapy, the combination of aspirin plus a proton pump inhibitor may be safer than clopidogrel alone, according to the American College of Cardiology 3
In patients requiring dual antiplatelet therapy who are at high risk for GI bleeding, concomitant PPI therapy should be considered, as advised by the American College of Cardiology 3

The American College of Chest Physicians recommends stopping clopidogrel 5 days before elective non-cardiac surgery 8, 9
The American College of Cardiology guidelines recommend withholding clopidogrel for at least 7 days before high-risk procedures 10
French guidelines recommend stopping clopidogrel 5 days before procedures with moderate-to-high bleeding risk 11
Dual antiplatelet therapy increases GI bleeding risk by up to 70% compared to monotherapy 10

Recent acute coronary syndrome (within past year) is a high thrombotic risk scenario that requires cardiology consultation before stopping clopidogrel 8, 9, 12
Remote myocardial infarction (>1 year) is a lower thrombotic risk scenario 13
Peripheral arterial disease alone is a lower thrombotic risk scenario 13, 11

Proton pump inhibitor (PPI) therapy is recommended for patients at increased risk of GI bleeding for as long as antithrombotic therapy is administered 13
Avoid omeprazole or esomeprazole as they significantly reduce clopidogrel's antiplatelet activity through CYP2C19 inhibition 13

The American College of Chest Physicians suggests resuming antiplatelet drugs ≤24 hours after surgery when appropriate 8

Clopidogrel causes irreversible platelet inhibition for 7-10 days, and restoration of platelet aggregation to at least 50% of normal requires a minimum of 5 days after discontinuation 10

The American College of Cardiology recommends that clopidogrel monotherapy carries a 9-14% rebleeding risk in patients with previous ulcer bleeding, which is actually higher than aspirin combined with a PPI 14
The American Heart Association suggests that higher loading doses (600 mg vs 300 mg) of clopidogrel increase major bleeding risk (2.5% vs 2.0%, P=0.012) 15
The European Society of Cardiology states that pantoprazole shows minimal CYP2C19 inhibition and is the preferred PPI if gastroprotection is needed 16
The European Heart Journal reports that the pharmacodynamic interaction between clopidogrel and PPIs has never been associated with significant adverse clinical outcomes in randomized trials 17

In patients receiving clopidogrel, overall bleeding occurs in 3.7 %–8.1 %, with gastrointestinal (GI) bleeding being the most frequent site, especially when clopidogrel is combined with aspirin. 18, 19
Major bleeding is observed in 3.7 % of patients on dual antiplatelet therapy (clopidogrel + aspirin) versus 2.7 % on aspirin alone, representing a 38 % relative increase in risk. 18, 19
GI bleeding is the predominant location of major hemorrhage, notably at femoral access sites in individuals undergoing cardiac procedures. 18, 19

Patients who undergo coronary artery bypass grafting (CABG) within 5 days of stopping clopidogrel experience higher bleeding rates (9.6 % vs 6.3 %, p = 0.06) compared with those who discontinue the drug ≥5 days before surgery. 18, 19, 20
Elective surgery should be scheduled after a minimum 5‑day clopidogrel‑free interval to limit major bleeding and the need for blood transfusion. 20
For urgent surgery, clopidogrel should be stopped at least 24 hours beforehand to reduce major bleeding complications. 20

The incidence of intracranial hemorrhage with clopidogrel is 0.1 %–0.4 %, comparable to aspirin’s rate of 0.1 %–0.5 %, with no statistically significant increase in hemorrhagic stroke. 21

TTP is a rare but potentially fatal adverse event that typically manifests within the first 2 weeks of initiating clopidogrel therapy. 21
Unlike ticlopidine, clopidogrel does not commonly cause neutropenia, making routine complete blood‑count monitoring unnecessary. 21

Omeprazole and esomeprazole markedly reduce clopidogrel’s antiplatelet effectiveness by inhibiting CYP2C19 metabolism, potentially increasing cardiovascular events. 21, 22
Pantoprazole is the preferred proton‑pump inhibitor when gastroprotection is required, because it exhibits minimal CYP2C19 inhibition. 21, 22
Clinical guidelines recommend using pantoprazole or an H₂‑blocker rather than omeprazole/esomeprazole for acid suppression in patients on clopidogrel. 21, 22

Plan elective procedures to allow a 5‑day discontinuation of clopidogrel before surgery. 20
Do not abruptly stop clopidogrel in patients with coronary stents without cardiology consultation, as premature discontinuation markedly raises the risk of stent thrombosis. 20

In patients with coronary stents who stop clopidogrel, the hazard ratio for death or myocardial infarction rises to 161 compared with continued therapy, indicating an extremely high risk of fatal thrombotic events. 23
After 5 days without clopidogrel, the risk of stent thrombosis markedly increases, and stent thrombosis is associated with a 40 % probability of subsequent myocardial infarction or death. 23